Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life

BACKGROUND: RATIONALE 302 (NCT03430843) an open-label, phase III study of second-line treatment of advanced/metastatic esophageal squamous cell carcinoma (ESCC), reported that tislelizumab, relative to investigator-chosen chemotherapy (ICC), was associated with improvements in overall survival and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Cutsem, E., Kato, K., Ajani, J., Shen, L., Xia, T., Ding, N., Zhan, L., Barnes, G., Kim, S.-B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434166/
https://www.ncbi.nlm.nih.gov/pubmed/35785595
http://dx.doi.org/10.1016/j.esmoop.2022.100517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434166/
https://www.ncbi.nlm.nih.gov/pubmed/35785595
http://dx.doi.org/10.1016/j.esmoop.2022.100517

Ejemplares similares